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Abstract
Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with 
Nuclear factor kappa B (NF-κB). The role of BTK in primary CNS lymphoma (PCNSL) is 
unknown. We performed a Phase 1 clinical trial with ibrutinib, the first-in-class BTK inhibitor, for 
patients with relapsed or refractory CNS Lymphoma. Clinical responses to ibrutinib occurred in 
10/13 (77%) PCNSL patients, including five complete responses. The only PCNSL with complete 
ibrutinib resistance harbored a mutation within the coiled-coil domain of Caspase Recruitment 
Domain Family Member 11, a known ibrutinib resistance mechanism. Incomplete tumor responses 
were associated with mutations in the B-Cell Antigen Receptor-associated protein CD79B. 
CD79B-mutant PCNSLs showed enrichment of mammalian target of rapamycin (mTOR)-related 
gene sets and increased staining with Phosphatidylinositol 3-kinase (PI3K)/mTOR activation 
markers. Inhibition of the PI3K-isoforms p110α/p110δ or mTOR synergized with ibrutinib to 
induce cell death in CD79B-mutant PCNSL cells.
INTRODUCTION
Diffuse large-B-cell lymphoma (DLBCL) represents the most common type of malignant 
lymphoma, accounting for 30% – 40% of newly diagnosed adults cases. Central nervous 
system (CNS) involvement, or “secondary” CNS lymphoma (SCNSL), occurs in a subset of 
DLBCL patients. Primary CNS lymphoma (PCNSL) is an aggressive lymphoma manifesting 
exclusively in the CNS. Almost all PCNSLs are DLBCLs. Many patients with CNS 
lymphoma suffer from disease recurrence following initial tumor therapy. Other patients 
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have refractory disease that fails to respond to first-line therapy. Patients with relapsed or 
refractory (r/r) CNS lymphoma respond poorly to currently available therapies (1–3).
Ibrutinib is a first-in-class, oral inhibitor of Bruton’s tyrosine kinase (BTK). BTK integrates 
B-cell antigen receptor (BCR) and Toll-like receptor (TLR)(4) signaling. Genes encoding 
members of these pathways frequently harbor mutations in DLBCL. These include the BCR-
associated protein CD79B (5) and myeloid differentiation primary response 88 (MYD88)(6), 
a cytosolic adapter protein that links interleukin-1 and TLRs with the Nuclear factor kappa B 
(NF-κB)(7). Activating mutations in MYD88 and CD79B have also been reported in 
PCNSL (8–12). Ibrutinib induced death of DLBCL cells with deregulated BCR signaling (5) 
and showed promising activity in a Phase 1 trial of patients with a variety of B-cell 
malignancies (13). Subsequent clinical trials reported 70–90% response rates to single-agent 
ibrutinib in patients with Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic 
Lymphoma (14), Mantle-Cell Lymphoma (MCL)(15), and Waldenström Macroglobulinemia 
(WM)(16). Response rates were considerably lower (~ 25%) in patients with r/r systemic 
DLBCL (17). Burkitt’s lymphoma cells, which are derived from germinal centre B cells, do 
not require BTK for survival (4,18).
The goals of the current study were to evaluate the tolerability of ibrutinib in patients with 
recurrent or refractory (r/r) CNS lymphoma, assess drug concentrations in cerebrospinal 
fluid (CSF), determine overall response rates, and explore molecular determinants of 
treatment response.
RESULTS
Study Design and Patient Demographics
This open-label, non-randomized, single center, dose escalation study was designed to 
establish the MTD of single-agent ibrutinib in r/r PCNSL/SCNSL. The defined MTD was 
used in an expansion cohort to further assess toxicity and clinical activity (NCT02315326). 
We explored drug doses above the recommended Phase 2 dose of 560 mg daily because 
plasma levels of ibrutinib have been reported to increase proportionally from 420 to 840 mg 
per day and because higher doses of ibrutinib have been administered in prior studies 
without reaching a maximum tolerated dose (MTD).
The primary end-points were safety of ibrutinib in CNS lymphoma and overall response rate 
(ORR) defined as complete and partial responders. The secondary end points were 
progression-free survival (PFS) and pharmacokinetics. Ibrutinib was administered 
continuously until disease progression, intolerable toxicity or death. The starting dose was 
560mg/day. Dose escalation among cohorts followed the "3+3" design and was allowed if, 
after 28 days of therapy, none of three or one of six patients had a DLT. Plasma and CSF 
samples were collected two hours after ibrutinib dosing on day 1 (cycle 1, day 1) and day 29 
(cycle 2, day 1).
Twenty eligible patients (Table 1) with r/r CNS lymphoma were enrolled. Median age was 
69 years (range, 21– 85). Twelve were women. The median ECOG score was 1 (range, 0–2). 
Thirteen had PCNSL and 7 had SCNSL; 14 patients had recurrent and 6 refractory disease. 
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Seventeen had parenchymal brain lesions, three isolated CSF involvement, and four both. 
Median number of prior therapies was two (range, 1–8), including methotrexate (MTX) 
chemotherapy (100%), radiotherapy (15%), and hematopoietic cell transplantation (15%). 
Eight patients had failed prior MTX-based salvage therapy, currently the most effective 
therapy for recurrent CNS lymphoma (19). Three patients received 560mg ibrutinib and 13 
patients received 840mg (Supplementary Tables S1/S2).
Ibrutinib Tolerability
Ibrutinib was tolerated with manageable adverse events (Table 2). No dose-limiting toxicity 
occurred during the dose-escalation portion of the study. The most common adverse events 
were hyperglycemia, thrombocytopenia, anemia, and hypertriglyceridemia. In the dose 
escalation cohort (n=10), three patients received 560mg and experienced one grade 4 
neutropenia (4 months after drug initiation), one grade 3 thrombocytopenia, and one grade 3 
ALT elevation. Seven patients received 840mg and developed one grade 4 lymphopenia and 
seven grade 3 toxicities, all except one (grade 3) occurring in the same patient (#5). In the 
expansion cohort (n=10), ten patients received 840mg. Four grade 4 toxicities (neutropenia 
(2), sepsis, lymphopenia) were observed in four patients and resolved after drug was held. 
Fifteen grade 3 toxicities were observed in six patients. Treatment was discontinued due to a 
fungal infection (grade 3) in one patient with MTX-refractory disease (patient #11) and 
chronic corticosteroids treatment for 17 weeks prior to enrollment. The patient developed 
pulmonary aspergillosis six weeks after initiating ibrutinib. New ring-enhancing lesions 
were detected on routine response evaluation, but CSF fungal and bacterial cultures were 
negative. Ibrutinib was held during antifungal therapy and the patient succumbed to disease 
progression 77 days after the last dose of ibrutinib. This was the only patient where 
treatment was discontinued due to toxicity. The ibrutinib dose was reduced in one patient 
(patient #13) with colitis from 840 to 560mg.
Ibrutinib concentration in CSF
We measured CSF ibrutinib concentrations two hours post-dose in 18/20 patients and 14/20 
patients at day 1 and day 29, respectively. The two hour time point was chosen based on the 
reported median time of ibrutinib peak plasma concentrations (14). CSF was collected from 
an Ommaya reservoir for patient #1, #3, and #18. CSF was collected through lumbar 
puncture in all other patients. Mean CSF ibrutinib concentration was 0.77ng/ml (1.7nM) and 
1.95ng/ml (4.4nM) in patients receiving 560mg and 840mg, respectively with a trend to 
higher CSF concentrations after one month of therapy (1.65ng/ml and 3.18ng/ml for patients 
receiving 560mg and 840mg respectively)(Supplementary Fig. S1).
Frequent Tumor Responses to Ibrutinib
Twelve of 13 PCNSL patients were evaluated for response. One patient (#7) was not 
evaluable because drug was discontinued within 14 days of treatment due to personal choice. 
10/13 (77%)(95% CI: 56%– 94%) patients showed a clinical response, including five 
patients with a complete response (CR) and five patients with a partial responses (PR). One 
additional patient (#19) experienced tumor regression that did not meet criteria for PR (Fig. 
1A and B). All three patients with malignant cells in the CSF at study entry showed no 
malignant cells on follow-up evaluation. At a median follow-up of 479 days (range, 354–
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739), two patients are still receiving treatment (Fig. 1C). Both had a CR as their best 
response. The median progression-free survival (PFS) was 4.6 months (95% CI: 2.4–7.5 
months). The median overall survival (OS) was 15 months (7/13 subjects still alive).
Five of seven (71%) SCNSL patients showed a clinical response, including 4 CRs (Fig. 1D 
and E). One patient is still receiving treatment and two patients were treated with high-dose 
chemotherapy and stem cell rescue after achieving a CR on single-agent ibrutinib. Four 
patients had CSF disease at enrollment. In 3/4 patients, malignant cells were no longer 
detectable on follow-up evaluation on ibrutinib. The median PFS in SCNSLs was 7.43 
months with a median OS that has not been reached yet (5/7 subjects still alive) (Fig. 1F).
Of the ten patients requiring corticosteroids to control neurologic symptoms at enrollment, 
six (60%) were successfully tapered off corticosteroids after initiating ibrutinib. None of the 
complete responses to single-agent ibrutinib in PCNSL could be attributed to concurrent 
corticosteroid use (Supplementary Table S3).
Genomic Landscape of PCNSL
The antitumor activity of ibrutinib in r/r PCNSL was considerably greater than reported for 
patients with r/r DLBCL outside the CNS (overall response rate/ORR 25% and median OS 
6.4 months)(17). To explore genetic differences between these two clinically distinct 
DLBCL entities, we examined the coding regions of 586 cancer-associated genes in 177 
archival human PCNSL biopsies and compared our findings to the genomic landscape of 
DLBCL outside the CNS, as reported in prior studies (20–22).
Twenty-six genes were recurrently mutated in PCNSL (Fig. 2A). Mutations in 23 additional 
genes could be attributed to aberrant somatic hypermutation (aSHM), the result of 
malfunctioning of the physiologic somatic hypermutation process (23). Five genes (PIM1, 
BTG2, PRDM1, TOX, and IRF4) scored as both recurrent mutations and targets of aSHM 
(Supplementary Table S4 and S5). Mutations in the Toll/IL-1 receptor (TIR) domain of the 
cytosolic adapter protein myeloid differentiation primary response 88 (MYD88) and the 
immunoreceptor tyrosine-based activation motif (ITAM) of the B-Cell Antigen Receptor-
associated protein CD79B occurred in 58% and 41 % of PCNSLs, a frequency that is 
consistent with prior PCNSL studies and considerably higher than reported for DLBCL 
outside the CNS (Supplementary Table S6). In contrast, we observed similar mutation 
frequencies for all other examined genes, including genes involved in immune escape (B2M, 
CD58), DNA and histone modifications (MLL2, CREBBP), and B cell differentiation 
(PRDM1)(Supplementary Fig. S2).
At the molecular level, DLBCL outside the CNS has been further classified into disease 
subgroups (24). Mutations in BCR pathway members have been shown to be enriched in the 
activated B-cell–like (ABC) DLBCL subgroup, but rarely found in the germinal center B-
cell–like (GCB) subgroup (5,6,25–27). We examined in PCNSL the association between 
disease subgroup and mutations in the four BCR-NF-κB pathway members MYD88, 
CD79B, Caspase Recruitment Domain Family Member 11 (CARD11) and Tumor Necrosis 
Factor Alpha-Induced Protein 3 (TNFAIP3, also known as A20). Unlike the more balanced 
distribution of disease subgroups in DLBCL outside the CNS, the vast majority of PCNSLs 
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(157/177) belonged to the non-germinal center (non-GCB) DLBCL subgroup 
(Supplementary Fig. S3) and we identified mutations in BCR-NF-κB pathway members in 
both GCB and non-GCB tumors (Fig. 2B).
Genomic Determinants of Ibrutinib Response in PCNSL
Our clinical trial findings and genomic analysis suggested that BTK dependence and BCR 
pathway mutations are distinguishing features of PCNSL compared to DLBCL outside the 
CNS. We therefore examined the relationship between BCR pathway mutations and clinical 
ibrutinib response in pretreatment tumor biopsies from our clinical trial patients. We 
observed a missense mutation within the coiled-coil domain of CARD11 (R179Q) in the 
only PCNSL patient with complete ibrutinib resistance (#5). Mutations in the coiled-coil 
domain of CARD11 have been shown to promote BTK-independent activation of NF-κB 
(25) and have been identified in patients with clinical ibrutinib resistance in DLBCL outside 
the CNS and in Mantle-Cell Lymphoma (17,28). Three other tumors with incomplete 
ibrutinib responsiveness showed a mutation in CARD11 (R337Q) or inactivating lesions in 
TNFAIP3 (deletion, frameshift mutation), a negative regulator of NF-κB (Table 3). 
Surprisingly, none of the PCNSLs with concurrent mutations in MYD88 and CD79B, a 
particularly common event in PCNSL (see Fig. 2B), showed a complete response to 
ibrutinib.
PI3K-mTOR axis promotes survival in CD79B-mutant PCNSL
Mutations in the first tyrosine (Y196D) of the immunoreceptor tyrosine-based activation 
motif (ITAM) of CD79B have been shown to impair BCR downregulation (5). We 
hypothesized that these mutations might attenuate BTK dependence by diversifying BCR 
signal output and providing a BTK-independent survival signal (Fig. 3A). To identify such 
signals, we isolated RNA from PCNSL biopsies with known CD79B status and compared 
the transcriptomes of CD79B-mutant and CD79B-wildtype PCNSLs using gene-set 
enrichment analysis (Broad MSigDB C2 pathways containing 4929 gene sets). Multiple 
gene sets associated with activated mTOR signaling were among the most highly enriched 
pathways in CD79B-mutant PCNSLs whereas gene sets associated with activated NF-κB 
were negatively enriched (Fig. 3B and Supplementary Table S7). We also stained CD79B-
mutant and CD79B-wildtype PCNSLs with antibodies against activated forms of the two 
PI3K/mTOR pathway components eukaryotic translation initiation factor 4E-binding protein 
1 (4E-BP1, Threonine 37/46) and S6 Ribosomal Protein (S6RP, Serine 240). A significantly 
higher fraction of CD79B-mutant than CD79B-wildtype PCNSLs stained with both 
antibodies (Fig. 3C). We also derived xenograft models (PDX) from two CD79B-mutant 
PCNSL biopsies. In both orthotopic PCNSL models, we observed diffuse infiltration of the 
mouse brain by CD20-positive tumor cells which stained briskly with antibodies against 
phosphorylated forms of S6RP and 4E-BP1 (Supplementary Fig. S4). Treatment of slice 
cultures from these xenograft tumors with the PI3K inhibitor BKM120 (29) induced cell 
death at concentrations that inhibited phosphorylation of the serine/threonine kinase AKT 
(Serine 473) and the mTOR targets S6RP and 4E-BP1 (Fig. 3D). Taken together, these data 
indicate that the PI3K/mTOR-signaling axis is constitutively activated and promotes survival 
in CD79B-mutant PCNSL.
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PI3K pathway activation in DLBCL occurs during both antigen-induced and antigen-
independent (or “tonic”) BCR activation (30), but is particularly critical for survival during 
tonic BCR signaling (31). Class I PI3Ks are heterodimers that contain a p85 regulatory 
subunit and one of four catalytic subunits isoforms (class IA: p110α, p110β, p110δ; class 
IB: p110γ). While all catalytic isoforms mediate the same enzymatic reaction, they serve 
unique functions in specific cell types and signaling contexts (32,33). We examined the 
contribution of specific PI3K isoforms with PI3K isoform-selective inhibitors (34) in a 
CD79B-mutant PCNSL cell line derived from one of the two CD79B-mutant PCNSL PDX 
models (Supplementary Fig. S5). Unlike BKM120, which inhibits all class I PI3K isoforms, 
isoform-selective inhibitors of p110α (BYL719), p110β (AZD6482), or p110δ (idelalisib) 
did not induce cell death (Supplementary Fig. S6). In contrast, we observed robust cell death 
induction when we blocked the p110α and p110δ isoforms together, either using the 
combination of BYL719 and idelalisib (Fig. 3E) or the p110α/p110δ-inhibitor BAY80-6946 
(Fig. 3F). These data indicate that p110α and p110δ PI3K isoforms provide redundant 
survival signals in CD79B-mutant PCNSL cells, reminiscent of the redundant pro-survival 
function of these two PI3K isoforms during tonic BCR signaling in normal B cells (35).
PI3K activates multiple downstream signaling pathways, including mTOR and BTK (36). 
We therefore wondered whether the survival signal mediated by PI3K p110α/p110δ was, at 
least in part, independent of BTK. Treatment of CD79B-mutant PCNSL cells with the BTK 
inhibitor ibrutinib resulted in dose-dependent reduction of BTK phosphorylation, NF-κB 
transcriptional activity, and tumor cell proliferation. However, we only observed cell death at 
ibrutinib concentrations around 10 nM (Supplementary Fig. S7), a concentration that was 
not achieved in cerebrospinal fluid for many PCNSL patients in our trial (see Supplementary 
Fig. S1). The combination of BAY80-6946 and ibrutinib, at concentrations at which neither 
drug induced cell death, resulted in synergistic cell death induction (Fig. 3G). Of note, the 
synergistic effect of the drug combination was not associated with further NF-κB inhibition 
(Fig. 3H), but more complete mTOR inhibition (Fig. 3I). We therefore also explored the 
combination of 1nM ibrutinib with the mTOR kinase inhibitor INK128 (37) and again 
observed synergistic cell death induction (Fig. 3J). Taken together, these results suggest that 
the survival signal provided by the PI3K/mTOR-axis is, at least in part, independent of 
BTK/NF-κB signaling.
DISCUSSION
Our study shows remarkable single-agent activity of ibrutinib in patients with recurrent or 
treatment-refractory PCNSL, including patients who had already failed prior MTX-based 
salvage therapy. Ibrutinib compared favorably to other therapies explored in this setting, 
including the mTOR inhibitor temsirolimus (PFS 2.1 months)(38), the combination of 
rituximab and temozolomide (PFS 1.6 months)(39), or topotecan (PFS 2 months)(40). While 
most PCNSL patients eventually developed resistance to ibrutinib, as seen with other kinase 
inhibitors in cancer (41), further evaluation of ibrutinib as part of combination therapies for 
PCNSL seems warranted. In contrast to a recent clinical trial that combined ibrutinib with 
temozolomide, etoposide, doxorubicin, dexamethasone, and rituximab for the treatment of 
PCNSL (42), we did not observe any treatment-related deaths and single-agent ibrutinib was 
tolerated with manageable toxicity in this heavily pretreated patient population.
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Kinase inhibitors are typically less active against cancer in the CNS than outside the CNS. It 
is therefore remarkable that responses to ibrutinib were more frequent in r/r PCNSL (77% 
ORR) than the reported response rate in r/r DLBCL outside the CNS (25% ORR)(17). This 
observation points toward a divergent pathogenesis of these two related diseases, further 
supported by our genomic landscape analysis. The difference in intrinsic “BTK dependence” 
between PCNSL and DLBCL outside the CNS might be due to specific genetic alterations. 
MYD88 mutations, for example, have been linked to ibrutinib sensitivity in Waldenström 
Macroglobulinemia (16) and are significantly more common in PCNSL than in DLBCL 
outside the CNS. Alternatively, the brain microenvironment might augment BTK 
dependence of lymphoma cells through chronic antigen presentation and BCR activation 
(43,44), perhaps explaining the observed greater than expected response rate to ibrutinib in 
SCNSL patients. Further studies are needed to determine how genetic and tumor 
microenvironmental factors, alone or in combination, create intrinsic BTK dependence in 
different B cell malignancies (4,18). In the meantime, our data suggests that clinical trials 
with BTK inhibitors in recurrent/refractory CNS lymphoma should include patients whose 
tumors lack mutations in the B-cell receptor signaling axis.
Lastly, our study provides a first glimpse into genetic mechanisms of de-novo ibrutinib-
resistance in PCNSL. The only PCNSL that was completely resistant to ibrutinib harbored a 
mutation in the coiled-coil domain of CARD11, a reported mechanism of ibrutinib 
resistance in other B cell malignancies (17,28). CD79B mutations, which are frequently 
associated with MYD88 mutations in PCNSL, appear to attenuate BTK “addiction” by 
providing a redundant survival signal, consistent with the recent observation of CD79B 
upregulation in ABC-DLBCL cell lines with reduced ibrutinib sensitivity (45). This 
resistance mechanism, while less dramatic than the effects of CARD11 mutations, is 
particularly relevant in the setting of incomplete BTK blockade. Our pharmacokinetic data 
suggests that clinically achievable ibrutinib concentrations in the CSF result in incomplete 
BTK inhibition. Direct measurement of BTK occupancy in CSF, if technically feasible, 
might provide further insight into this important question. Combination therapy of ibrutinib 
with inhibitors of p110α/p110δ PI3K or mTOR, which are in advanced stages of clinical 
testing, may offer a strategy to augment the depth and duration of ibrutinib responses in 
CD79B-mutant PCNSL and perhaps other DLBCL subgroups (46). Further studies are 
needed to evaluate if second generation BTK inhibitors with different pharmacokinetic 
properties and kinase selectivity might augment the remarkable clinical activity of ibrutinib 
in CNS lymphoma.
METHODS
Study oversight
Pharmacyclics LLC, an AbbVie company, provided the study drug. All authors collected the 
data and all the authors interpreted the results. This study was conducted with appropriate 
ethical approval. The protocol and its amendments were approved by the Institutional 
Review Board of Memorial Sloan Kettering Cancer Center. All participants provided written 
informed consent. This study was conducted in accordance with the Declaration of Helsinki 
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and International Conference on Harmonization Guidelines for Good Clinical Practice. 
ClinicalTrials.gov: (NCT02315326) https://clinicaltrials.gov/ct2/show/NCT02315326
Eligibility
The trial population comprised patients with recurrent/refractory (r/r) PCNSL or SCNSL. 
All subjects had histopathologic confirmation of diagnosis. Patients met the following 
criteria: age ≥18; r/r disease on imaging or CSF; completion of at least one prior CNS-
directed therapy; Eastern Cooperative Oncology Group (ECOG) performance status score of 
0–2; adequate bone marrow and organ function; recovery to grade 1 toxicity from prior 
therapy. Patients with active non-CNS disease, prior ibrutinib therapy, or requiring >8mg of 
dexamethasone daily for neurologic disability were excluded.
Pharmacokinetic Evaluation
Plasma and CSF samples were collected two hours after ibrutinib dosing on day 1 (cycle 1, 
day 1) and day 29 (cycle 2, day 1). In patients with an Ommaya reservoir, plasma and CSF 
were collected 0, 1, 2, 3, 4, 6, and 24 hours after drug administration on day 1 (cycle 1, day 
1) and 1, 2, 3, 4, and 6 hours after drug administration on day 29 (cycle 2, day 1).
Adverse Event Grading
Adverse events were graded using the NCI Common Terminology Criteria for Adverse 
Events (4.0). Dose limiting events (DLTs) were defined as any grade 4 hematologic toxicity, 
grade 3 febrile neutropenia and grade 3 thrombocytopenia associated with bleeding or any 
grade 3 non-hematologic toxicity that did not respond to supportive therapy and at least 
possibly related to treatment with ibrutinib.
Treatment Response Assessments
Evaluation of treatment response followed the International Primary CNS Lymphoma 
Collaborative Group guidelines (47).
Statistical Analysis
Descriptive statistics, including means, standard deviations, and medians for continuous 
variables and proportions for discrete variables, were used to summarize the findings in each 
of the defined cohorts. All analyses included patients who received the study drug. The ORR 
with a 95% confidence interval was calculated. The Kaplan–Meier method was used for 
time-to-event analysis. PFS was defined as time from ibrutinib start to progression, death or 
date of last follow-up scan with no documented progression. No imputation of missing 
values was performed. The primary objective of this phase I trial was to define the MTD of 
ibrutinib. Aim of the expansion portion was the assessment of ORR and progression-free 
survival at 24 weeks (PFS24w) rate of patients receiving ibrutinib. Patients from the 
expansion cohort as well as from the MTD were used to estimate the ORR and PFS rate. 
PFS24w was estimated along with a 95% confidence interval. PFS24w was defined as the 
percentage of patients that have not developed progression of disease or died without 
progression at 24 weeks from the start of treatment. All patients were followed for at least 
24 weeks. Based on an accrual of 16 participants at the MTD the two-sided 95% binominal 
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confidence intervals for a PFS24w of 60% (8/16 still on trial) were 24.1 and 75.4%. 
Additionally, if a complete response (CR) was seen in >1 patient, the investigational drug 
was deemed promising for additional clinical studies. Frequencies of single genes in the 
PCNSL and non-CNS DLBCL datasets were compared using the student T-test.
Immunohistochemistry (IHC)
Archival pretreatment tumor samples were obtained from patients participating in the 
clinical trial and from archival tissues. All samples were studied in accordance with a 
protocol approved by the Memorial Sloan Kettering Cancer Center Institutional Review 
Board. Formalin-fixed paraffin-embedded tissue from pre-treatment tumor biopsies from all 
study participants was used for IHC and sequencing. FFPE samples were sectioned at 5µm 
thickness. The first and last section was used for Hematoxylin and Eosin (H&E) staining to 
determine tumor content. All samples were reviewed by a neuropathologist (JTH) to confirm 
the histopathologic diagnosis of PCNSL.
We performed additional studies in archival tumor biopsies to evaluate the frequency of 
DLBCL subtypes and genetic alterations in a larger number of PCNSLs (n=177). These 
archival samples included tumors from MSK, Kaiser-Permanente Northern California, and 
the Radiation Therapy Oncology Group. Assignment to DLBCL subtype was based on 
established IHC criteria(48). To determine DLBCL subtype, FFPE tumor biopsies were 
stained with antibodies against CD10 (Vector Laboratories, Burlingame, CA), B-cell CLL/
lymphoma 6 (BCL6)(GI191E/A8, Ventana/Roche), melanoma associated antigen (mutated) 
1 (MUM1)(Dako/Agilent, Carpinteria, CA), phospho S6 Ribosomal protein (Ser 240/244)
(Cell Signaling, Danverse, MA) and phospho 4EBP1 (Thr37/46)(Cell Signaling, Danverse, 
MA).
Genomic Analysis and in vitro experiments
Tumor biopsies were obtained before treatment from patients participating in the clinical 
trial and from archival tissues. All samples were studied in accordance with a protocol 
approved by the Memorial Sloan Kettering Cancer Center Institutional Review Board. 
Additional details on genomic analysis and in vitro experiments using PCNSL patient-
derived xenograft models and cell line are available "online only".
Genomic analysis
All RNA and DNA sequencing of human tumor samples and Data Analysis was performed 
at Memorial Sloan Kettering Cancer Center. RNA was isolated from 31 primary CNS 
lymphoma samples and profiled on the Illumina Human HT12 V4 platform. To detect 
outliers, we used the detection p-value information of the raw data output and spearman 
correlation of each sample to a median pseudo-sample (49). Three samples with low 
detection and poor correlation to the median sample were excluded from further 
preprocessing and downstream analyses. The data were quantile normalized. A strong 
correlation was detected between the first principal component of the data and two 
annotation variables of presumed biological irrelevance: the time in paraffin and the source 
trial. This confounding signal was removed using the R language package “swamp” (https://
cran.r-project.org/web/packages/swamp/index.html) prior to downstream analyses and 
Grommes et al. Page 10
Cancer Discov. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
visualization. We used the gene-set-enrichment analysis (GSEA) algorithm (50) and 
pathway annotation defined by the Molecular Signatures Database (MSigDB) C2 collection 
(version 2.5) of canonical signaling pathways, cellular processes, chemical and genetic 
perturbations, and human disease states(50) as previously described (51).
DNA isolation, sequencing library preparation and sequencing on a HiSeq 2500 was 
performed as described by Cheng DT et al. (52). Hybridization capture was preformed using 
the MSK-HemePACT targeted panel including the following 585 cancer genes (please see 
Supplementary Methods for complete gene list). All samples from study participants had a 
matching germline sample. The archival samples did not have a matching germline sample. 
Read alignment and processing were performed using standard parameters. The GATK tool 
was use for local realignment and quality score recalibration as of GATK best practices. 
Mutation analysis was performed using Mutect v 1.1.7(53) and GATK Haplotype Caller. 
Germline polymorphisms and sequencing artifacts were excluded by paired analysis if 
matched normal was available, and by filtering with a panel-of-normal samples. Known 
germline polymorphisms were excluded if present in the Exome Sequencing Project or at 
frequencies >1% in Exome Aggregation Consortium population databases. Initially, we 
eliminated known SNPs that are present in >1% of the population or a panel of normal 
controls and identified 5024 somatic mutations in 513 genes. We determined recurrently 
mutated genes using MutSig(54) and Oncodrive(55) algorithms. We used previously 
published criteria(56) to determine whether a mutation was the result of aberrant somatic 
hypermutation. DNA from a PCNSL cell line and patient primary tumor was used for array 
comparative genomic hybridization (array CGH) using a protocol provided by Agilent 
Technologies. aCGH data were analyzed and processed using Agilent Cytogenomics 
software version 1.5.
PCNSL Disease Models
Fresh samples were collected from patients undergoing diagnostic biopsy at MSKCC. The 
patient signed informed consent for use of tissue for research purposes under protocols 
approved by the Memorial Sloan Kettering (MSK) Cancer Center Institutional Review 
Board The samples were mechanically dissociated as well as enzymatically treated with 
Accumax (Innovative Cell Technologies). Cells were counted and checked for viability prior 
to injection into the striatum of SCID mice. At time of development of neurologic deficits, 
mice were sacrificed and brains were removed in a sterile fashion. 300µm thick tumor 
containing brain slices were generated by using a vibratome (Leica 1200 S). Tissue slices 
were cultured on organotypic inserts (Millipore). Organotypic inserts are Teflon membranes 
with 0.4-µm pores that allow preservation of 3D tissue structure in culture. Tissue culture 
was performed at 37 °C in a 5% CO2 humidified incubator using 1 ml of RPMI with 10% 
FBS (Omega Scientfic) and 100 U/mL penicillin/100 µg/mL streptomycin (Gemini Bio-
Products). Tumor containing brain slices were treated with BKM120. DMSO was used in 
matched control samples. Tissue slices were harvested at 24h post-treatment and snap-frozen 
for western blot analysis. A PCNSL cell line (PCNSL-MSK) was derived from a patient 
derived xenograft model. PCNSL-MSK was cultured in RPMI, 5% fetal bovine serum and 
1% penicillin/ streptomycin. NF-κB activity was measured in nuclear protein extracts by the 
TransAM NF-κB p65 protein assay (Active Motif, Carlsbad, CA, USA), an ELISA-based 
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method to quantify NF-κB p65 subunit activation. The assay was performed according to the 
manufacturer's protocol and analyzed using a microplate absorbance reader. The BTK 
inhibitor ibrutinib and the PI3K pan and isoform inhibitors BKM120, BYL719, AZD6482, 
idelalisib, and BAY80-6946 were purchased from Selleck Chemicals. The cell lines Raji, 
Jurkat, SUDHL-4, SUDHL-5, SUDHL-6, SUDHL-10 were purchased from ATCC. The cell 
lines OCI-LY2, OCI-LY3, and OCI-LY13 were provided by Dr. Chaganti (MSKCC). All 
lymphoma cell lines were cultured in RPMI, 10% FBS. The cell line PCNSL#11 was 
generated from the orthotopic xenograft model PCNS#11 and maintained in RPMI and 10% 
FBS. Mouse B cells were isolated as previously described (57).
Immunoblotting
Snap-frozen tissues or cell culture cells were lysed and homogenized in 1% triton lysis 
buffer (#9803, Cell Signaling) containing fresh protease and phosphatase inhibitors by 
standard procedures. Protein concentrations were quantified with the BCA Protein Assay kit 
(Pierce Chemical Co.), and proteins were separated in a gradient (4–15%) SDSPAGE gel, 
transferred to nitrocellulose membranes, and hybridized with antibodies to the indicated 
antigens by standard procedures. Signals were detected by chemoluminescence using ECL 
detection reagents (Amersham Pharmacia Biotech). Primary antibodies to the following 
antigens were used: cleaved PARP (Asp214/D64E10 XP, #5625, Cell Signaling), cleaved 
caspase-3 (Asp175, #9661, Cell Signaling), Vinculin (clone hVIN-1, V9131, Sigma), BTK 
(#8546, Cell Signaling), phospho-BTK (#5083, Tyr223Y223, Cell Signaling), phospho-S6 
Ribosomal protein (#2211, Ser 235/236, Cell Signaling), phospho-4EBP1 (#2855, Thr37/46, 
Cell Signaling) and phospho-AKT (#4060, Ser473, Cell Signaling).
Immunohistochemistry and computer-assisted image analysis of xenograft models
Paraffin-embedded sections of tumor xenografts were obtained at 5µm/slide. Antigen 
retrieval, immunohistochemical detection and counter staining were performed using the 
Ventana Discovery Ultra autostainer (Ventana) using primary antibodies against pS6 
(S240/244), p4EBP1 (T37/46), and Ki67 (M7240, Dako). Digitized images were taken from 
representative areas within the xenografts.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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STATEMENT OF SIGNIFICANCE
Ibrutinib has substantial activity in patients with relapsed or refractory B cell lymphoma 
of the CNS. Response rates in PCNSL were considerably higher than reported for 
DLBCL outside the CNS, suggesting a divergent molecular pathogenesis. Combined 
inhibition of BTK and PI3K/mTOR may augment the ibrutinib response in CD79B-
mutant human PCNSLs.
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Figure 1. Clinical Response to Ibrutinib in recurrent/refractory CNS Lymphoma
A, Representative tumor response to ibrutinib as determined by magnetic resonance imaging 
(MRI) T1+contrast sequences in a Primary CNS Lymphoma (PCNSL; patient #3). B, Best 
response to ibrutinib in PCNSL patients, assessed using International PCNSL Collaborative 
Group (IPCG) guidelines (47). Displayed is the change in target lesion diameter from 
baseline (%) by magnetic resonance imaging or clearance of cerebrospinal fluid; negative 
values indicate tumor shrinkage. Shown are subjects who underwent at least 15 days of drug 
treatment and one post-treatment evaluation. Dashed lines indicate 25% change. Black: 
progression of disease (PD); orange: stable disease (SD); blue: partial response (PR), and 
green: complete response (CR). C, Progression-free survival in PCNSL. ➙, patient still 
receiving ibrutinib; #, drug discontinued because of personal choice (#4, #7) or infection 
(#11); ◆, progression. CR, complete response; PR, partial response; SD, stable disease; PD, 
progressive disease; n/a, not assessable. Two patients withdrew from treatment despite 
clinical and radiographic response (#4, #7). Treatment was discontinued due to a fungal 
infection (grade 3) in one patient (#11) with MTX-refractory disease. The ibrutinib dose was 
reduced in one patient with colitis (#13) from 840 to 560mg. D, Representative tumor 
response to ibrutinib in a Secondary CNS Lymphoma (SCNSL; patient #15). E, Best 
response to ibrutinib in SCNSL. Shown are subjects who underwent at least 15 days of drug 
treatment and one post-treatment evaluation. Dashed lines indicate 25% change. Black: 
progression of disease (PD); orange: stable disease (SD); blue: partial response (PR), and 
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green: complete response (CR). F, Progression-free survival in SCNSL. ➙, patient still 
receiving ibrutinib; *, hematopoietic stem cell transplantation (in CR); ◆, progression. CR, 
complete response; PR, partial response; SD, stable disease; PD, progressive disease; n/a, 
not assessable.
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Figure 2. Genomic Landscape of PCNSL
A, Shown are mutation frequencies in PCNSLs (n=177), grouped into genes with recurrent 
somatic mutations, genes affected by aberrant somatic hypermutation, and genes meeting 
both criteria (see Supplementary Table S5). B, Relationship between PCNSL disease 
subtypes and mutations in BCR pathway members in PCNSL. The disease subtype is shown 
in the top row and was determined by IHC (GCB: germinal center B-cell like; non-GCB: 
non-germinal center B-cell like; T-cell). Missense mutations are displayed in green, in-frame 
mutations in grey, truncating mutations in black, amplifications in red and deletions in blue.
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Figure 3. PI3K/mTOR pathway promotes survival in CD79B-mutant PCNSL
A, Cartoon of the BCR/NFκB signaling axis. Genes harboring mutations in PCNSL are 
highlighted in red. B, Gene-set enrichment analysis (GSEA) of PCNSL biopsies shows 
enrichment of mTOR related gene sets in CD79B-mutated PCNSL. C, Activation of PI3K/
mTOR in CD79B-mutant PCNSL. PCNSL tissue was stained with antibodies against 4EBP1 
(T37/46) and S6 Ribosomal protein (S240/244). Tumors staining with both antibodies, 
labeled as “double positive”, were more common in CD79B-mutated PCNSL than in 
CD79B-wildtype PCNSL. (see bargraph on top ****: p<0.0001). The images below the 
bargraph show representative IHC images for a “double-positive” (left column) and “double-
negative” (right column) PCNSL. D, BKM120, a pan-class I PI3K inhibitor, induces cell 
death in slice cultures from two CD79B-mutant PCNSL xenograft models. Shown are 
Western Blots of whole cell lysates after incubation for 24 hours with the indicated 
concentrations of BKM120. E, Combination of the PI3Kα-specific inhibitor BYL719 and 
the PI3Kδ-specific inhibitor Idelalisib, but neither inhibitor alone, induces cell death in a 
CD79B-mutant PCNSL cell line. F, The PI3Kα/δ specific inhibitor BAY 80-6946 induces 
cell death in PCNSL-MSK cells. G, Synergistic cell death induction by combination of 
ibrutnib and BAY 80-6946. H, Combination of ibrutnib and BAY 80-6946 is not associated 
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with further NF-κB inhibition. n. oligo, oligonucleotides with the NF-κB binding domain 
are added and serve as a negative control for the assay. ***: p<0.001 I, Increased inhibition 
of the PI3K/mTOR pathway by combination of ibrutinib and BAY 80-6946; shown are 
Western Blots. J, Synergism between Ibrutinib and the dual mTOR inhibitor INK128 in 
PCNSL-MSK cells. ****: p<0.0001.
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Table 1
Baseline Characteristics of Patients (n=20)
Characteristics All (n=20) PCNSL (n=13) SCNSL (n=7)
Age - years No. No. No.
Median 69 69 61
Range 21–85 60–80 21–85
Gender no (%) no (%) no (%)
Male 8 (40) 5 (38) 3 (43)
Female 12 (60) 8 (62) 4 (57)
ECOG No. No. No.
Median 1 1 1
Range 0–2 0–2 0–2
CNS Lymphoma No. (%) No. (%) No. (%)
Primary (PCNSL) 13 (65) 13 (100) n/a
Secondary (SCNSL) 7 (35) n/a 7 (100)
Disease Status No. (%) No. (%) No. (%)
Recurrent 14 (70) 10 (77) 4 (57)
Refractory 6 (30) 3 (23) 3 (43)
CNS Involvement No. (%) No. (%) No. (%)
Brain 13 (65) 10 (77) 3 (43)
Cerebrospinal fluid (CSF) 3 (15) 2 (15) 1 (14)
Brain and CSF 4 (20) 1 (8) 3 (43)
Prior Treatment No. (%) No. (%) No. (%)
Chemotherapy 20 (100) 13 (100) 7 (100)
Radiation 3 (15) 2 (15) 1 (14)
Stem cell transplant 3 (15) 0 (0) 3 (43)
Number of Prior Regimens No. No. No.
Median 2 2 2
Range 1–8 1–8 1–3
ECOG PS: Eastern Cooperative Oncology Group Performance Status, CNS: Central Nervous System, PCNSL: Primary Central Nervous System 
Lymphoma, SCNSL: Secondary Central Nervous System Lymphoma
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Table 2
Treatment related adverse events
Adverse Event* Grade 1–2 Grade 3–4 Total
Number of patients (percent)
Hyperglycemia 16 (80) 3 (15) 19 (95)
Thrombocytopenia 12 (60) 2 (10) 14 (70)
Anemia 13 (65) 1 (5) 14 (70)
Hypertriglyceridemia 13 (65) 1 (5) 14 (70)
Cholesterol high 12 (60) 0 12 (60)
Alanine aminotransferase increased 8 (40) 2 (10) 10 (50)
Hypoalbuminemia 10 (50) 0 10 (50)
Hyponatremia 7 (35) 1 (5) 8 (40)
Aspartate aminotransferase increased 8 (40) 0 8 (40)
White blood cell decreased 4 (20) 2 (10) 6 (30)
Hypocalcemia 5 (25) 1 (5) 6 (30)
Activated partial thromboplastin time prolonged 4 (20) 2 (10) 6 (30)
Alkaline phosphatase increased 6 (30) 0 6 (30)
Creatinine increased 6 (30) 0 6 (30)
Neutropenia 2 (10) 3 (15) 5 (25)
Blood bilirubin increased 4 (20) 1 (5) 5 (25)
Diarrhea 5 (25) 0 5 (25)
Lymphopenia 1 (5) 4 (20) 5 (25)
Edema limbs 4 (20) 0 4 (20)
Mucositis 4 (20) 0 4 (20)
Cramping 4 (20) 0 4 (20)
Headache 3 (15) 0 3 (15)
Urinary tract infection 2 (10) 1(5) 3 (15)
Anorexia 2 (10) 0 2 (10)
Epistaxis 2 (10) 0 2 (10)
Hyperkalemia 2 (10) 0 2 (10)
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Adverse Event* Grade 1–2 Grade 3–4 Total
Number of patients (percent)
Hypernatremia 2 (10) 0 2 (10)
Sinusitis 2 (10) 0 2 (10)
Lung infection 0 2 (10) 2 (10)
Rash 2 (10) 0 2 (10)
Colitis 0 1 (5) 1 (5)
Encephalitis 0 (0) 1 (5) 1 (5)
Febrile neutropenia 0 1 (5) 1 (5)
Sepsis 0 1 (5) 1 (5)
*National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0
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